Kamran Ghoreschi

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)
    Kamran Ghoreschi
    Molecular Immunology and Inflammation Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 186:4234-43. 2011
  2. pmc Janus kinases in immune cell signaling
    Kamran Ghoreschi
    Molecular Immunology and Inflammation Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Immunol Rev 228:273-87. 2009
  3. pmc Selectivity and therapeutic inhibition of kinases: to be or not to be?
    Kamran Ghoreschi
    Molecular Immunology and Inflammation Branch, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Nat Immunol 10:356-60. 2009
  4. pmc Generation of pathogenic T(H)17 cells in the absence of TGF-β signalling
    Kamran Ghoreschi
    Molecular Immunology and Inflammation Branch, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 467:967-71. 2010
  5. pmc Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1
    Kiyoshi Hirahara
    Molecular Immunology and Inflammation Branch, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Immunity 36:1017-30. 2012
  6. pmc Tissue inhibitor of metalloproteinase 1 is preferentially expressed in Th1 and Th17 T-helper cell subsets and is a direct STAT target gene
    Adewole Adamson
    Molecular Immunology and Inflammation Branch, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA
    PLoS ONE 8:e59367. 2013
  7. pmc T helper 17 cell heterogeneity and pathogenicity in autoimmune disease
    Kamran Ghoreschi
    Molecular Immunology and Inflammation Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA
    Trends Immunol 32:395-401. 2011
  8. pmc Helper T-cell differentiation and plasticity: insights from epigenetics
    Kiyoshi Hirahara
    Department of Lymphocyte Cell Biology Section, Molecular Immunology and Inflammation Branch, National Institutes of Arthritis, and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892 1930, USA
    Immunology 134:235-45. 2011
  9. pmc Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5
    Xiang Ping Yang
    Molecular Immunology and Inflammation Branch, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Nat Immunol 12:247-54. 2011
  10. pmc Signal transduction pathways and transcriptional regulation in Th17 cell differentiation
    Kiyoshi Hirahara
    Lymphocyte Cell Biology Section, Molecular Immunology and Inflammation Branch, National Institutes of Arthritis, and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Cytokine Growth Factor Rev 21:425-34. 2010

Collaborators

Detail Information

Publications11

  1. pmc Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)
    Kamran Ghoreschi
    Molecular Immunology and Inflammation Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 186:4234-43. 2011
    ..Thus, CP-690,550 may improve autoimmune diseases and prevent transplant rejection by suppressing the differentiation of pathogenic Th1 and Th17 cells as well as innate immune cell signaling...
  2. pmc Janus kinases in immune cell signaling
    Kamran Ghoreschi
    Molecular Immunology and Inflammation Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Immunol Rev 228:273-87. 2009
    ..Despite the fact that Jaks were discovered only a little more than a decade ago, at the time of writing there are 20 clinical trials underway testing the safety and efficacy of Jak inhibitors...
  3. pmc Selectivity and therapeutic inhibition of kinases: to be or not to be?
    Kamran Ghoreschi
    Molecular Immunology and Inflammation Branch, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Nat Immunol 10:356-60. 2009
    ..In this Perspective, we discuss the present status of Janus kinase inhibitors-a new class of immunosuppressive drugs-and the advantages and disadvantages of selectively inhibiting this class of kinase...
  4. pmc Generation of pathogenic T(H)17 cells in the absence of TGF-β signalling
    Kamran Ghoreschi
    Molecular Immunology and Inflammation Branch, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 467:967-71. 2010
    ..These data indicate an alternative mode for T(H)17 differentiation. Consistent with genetic data linking IL23R with autoimmunity, our findings re-emphasize the importance of IL-23 and therefore may have therapeutic implications...
  5. pmc Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1
    Kiyoshi Hirahara
    Molecular Immunology and Inflammation Branch, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Immunity 36:1017-30. 2012
    ..Thus, these data identify a suppressive activity of IL-27, by which CD4(+) T cells can restrict differentiation of Th17 cells in trans...
  6. pmc Tissue inhibitor of metalloproteinase 1 is preferentially expressed in Th1 and Th17 T-helper cell subsets and is a direct STAT target gene
    Adewole Adamson
    Molecular Immunology and Inflammation Branch, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA
    PLoS ONE 8:e59367. 2013
    ..Finally, we demonstrate that when restricted to T cells, expression of TIMP1 promotes neuropathology in experimental allergic encephalomyelitis...
  7. pmc T helper 17 cell heterogeneity and pathogenicity in autoimmune disease
    Kamran Ghoreschi
    Molecular Immunology and Inflammation Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA
    Trends Immunol 32:395-401. 2011
    ..Ideally, better understanding of expression and action of key transcription factors and the epigenetic landscape of Th17 can help explain the flexibility and diversity of interleukin-17-producing cells...
  8. pmc Helper T-cell differentiation and plasticity: insights from epigenetics
    Kiyoshi Hirahara
    Department of Lymphocyte Cell Biology Section, Molecular Immunology and Inflammation Branch, National Institutes of Arthritis, and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892 1930, USA
    Immunology 134:235-45. 2011
    ..In this review, we will discuss recent progress in the understanding of how cytokines influence gene expression and epigenetic modifications, and the impact of these findings on our views of helper cell lineage commitment and plasticity...
  9. pmc Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5
    Xiang Ping Yang
    Molecular Immunology and Inflammation Branch, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Nat Immunol 12:247-54. 2011
    ..Thus, the balance rather than the absolute magnitude of these signals determined the propensity of cells to make a key inflammatory cytokine...
  10. pmc Signal transduction pathways and transcriptional regulation in Th17 cell differentiation
    Kiyoshi Hirahara
    Lymphocyte Cell Biology Section, Molecular Immunology and Inflammation Branch, National Institutes of Arthritis, and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Cytokine Growth Factor Rev 21:425-34. 2010
    ..In this review, we will discuss the current understanding of the signaling pathways, molecular interactions, and transcriptional and epigenetic events that contribute to Th17 differentiation and acquisition of effector functions...
  11. pmc Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550)
    Jian Kang Jiang
    NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, USA
    J Med Chem 51:8012-8. 2008
    ..Finally, an appraisal of the minimum energy conformation of each stereoisomer and molecular docking at Jak3 was performed in an effort to better understand each compounds selectivity and potency profiles...